Our most recent experimental data support the conclusion that murine VSELs fulfill all the in vitro criteria listed in Table I.
These data imply important potentials of the PLAP/anti-PLAP system for immunolocalisation and therapy in patients, but also emphasise that in vitro criteria alone are not reflected in in vivo tumour localisation capacities of antibodies.
With respect to the other in vitro criteria of pluripotency (Table I), murine VSELs also possess bivalent domains in promoters that encode developmentally important homeobox-containing transcription factors (Sox21, Nkx2.2, Dlx1, Lbx1h, Hlxb9, Pax5, and HoxA3) [ 68].
Therefore, it is recommended to determine in vitro criteria, which could be used to predict clinical resistance and susceptibility with acceptable accuracy, by testing representative number of clinical isolates [ 4, 5].
In this review the authors discuss the involvement of specific macrophage subpopulations in these processes and the complexity of defining macrophage subpopulations in vivo, since the in vitro criteria used to define M1 and M2 macrophages cannot be strictly applied to in vivo settings.
With this type of release mechanism, it may be best to employ a risk-based approach when setting the in vitro release criteria.
Composite hydrogels of drug-loaded poly(lactide-co-glycolide) (PLGA) nanoparticles dispersed in this biopolymer matrix meet the in vitro design criteria for prolonged local release.
This review introduces the structural and functional activities of the IgG class of recombinant antibodies, in vitro, and criteria that determine choice between the four subclasses.
Similarly, analysis of in-house data from Pfizer demonstrates that most of the compounds satisfying both cell permeability and in vitro clearance criteria fall into a logD range between 0 and 3 [5].
Potential mechanisms which CMV could use as a cofactor have been described in vitro and potential criteria for assessing cofactor activity in vivo have been proposed.
